Long acting insulin dose response modelling in type 2 diabetes

Tinna Björk Aradóttir, H. Bengtsson, M. L. Jensen, Niels Kjølstad Poulsen, Dimitri Boiroux, S. Schmidt, K. Norgaard

Research output: Contribution to journalConference abstract in journalResearchpeer-review


More than 60% of type 2 diabetes (T2D) patients in USA treated with insulin do not reach recommended HbA1c goals and a titration period can last for years. Connected devices and dose guidance tools are emerging to support this patient group in reaching better outcomes. We aim to develop a dose response model of long acting insulin to glucose dynamics to support emerging digital health and dose guidance solutions.
We perform a clinical study to collect continuous glucose monitoring (CGM) data during a long acting insulin titration period. We use the high frequency glucose data and insulin data to create a dose response model of each individual. The aim is to identify a suitable model structure of fasting glucose to long acting insulin dynamics.
The clinical study is a single centre, one arm exploratory feasibility study. We include insulin naïve adults with T2D. All patients are equipped with a smartphone, a BG meter, and a CGM during the trial period of up to 12 weeks. The primary endpoint of the study is how well a linear dose response model, given two weeks of data, can predict the dose needed to reach a target glucose level, evaluated at the end of study. We observe that a dose response model at two weeks can adequately describe the fasting glucose response at a later stage in treatment intensification.
Original languageEnglish
JournalDiabetes Technology & Therapeutics
Issue numberS1
Pages (from-to)A70-A70
Publication statusPublished - 2019
Event12th International Conference on Advanced Technologies & Treatments for Diabetes - CityCube Berlin, Berlin, Germany
Duration: 20 Feb 201923 Feb 2019
Conference number: 12


Conference12th International Conference on Advanced Technologies & Treatments for Diabetes
LocationCityCube Berlin


Dive into the research topics of 'Long acting insulin dose response modelling in type 2 diabetes'. Together they form a unique fingerprint.

Cite this